Date of announcement  2018/09/25
Time of announcement  19:04:40
 
Date of events   2018/09/25 
To which item it meets paragraph 21
Statement 
1.Date of the shareholders' meeting resolution:2018/09/25
2.Name and title of the director with permission to engage in competitive
  conduct:Paul Yang /Director
3.Items of competitive conduct in which the director is permitted to engage:
Engaged in business of other companies that are within or
similar to the business scope of CDIB Capital Group.
4.Period of permission to engage in the competitive conduct:
Appointment term.
5.Circumstances of the resolution (please describe the results of the voting
  under Article 209 of the Company Act):
Approved by the board of directors without the
attendance of the interested director.
6.If the permitted competitive conduct is business of a mainland China area
  enterprise, the name and title of the director (if it is not business of a
  mainland China area enterprise, please enter ”not applicable” below):
 Paul Yang /Director
7.Company name of the mainland China area enterprise and the director's
  position in the enterprise:
SinoCare Group Holdings Limited/Legal Representative
and Executive Director
8.Address of the mainland China area enterprise:
Room 201, Building A, No. 1 Qianwan 1st Road, Qianhai
Shenzhen-Hong Kong Cooperation Zone, Shenzhen
9.Business items of the mainland China area enterprise:
Investment in medical industry.
10.Degree of effect on the Company's finances and business:None.
11.If the director has invested in the mainland China area enterprise, the
   monetary amount of the director's investment and the director's
   shareholding ratio:None.
12.Any other matters that need to be specified:
The BOD is authorized to exercise the rights of the
shareholders' meeting pursuant to Article 15 of the
Financial Holding Company Act.